[CNP_P14] Poster Session 14

Sat. Oct 12, 2019 4:40 PM - 5:25 PM Poster Hall (Multi-purpose Hall)

座長：香月あすか（産業医科大学医学部精神医学教室）

10月11日（金）　13:40～15:10　ポスター会場（福岡国際会議場 2階多目的ホール）
10月12日（土）　16:40～17:25　ポスター会場（福岡国際会議場 2階多目的ホール）

+Add all to schedule

Cancelled

4:40 PM - 4:48 PM

[CNP-P14-1] Chronic blonanserin administration attenuates neuroinflammation in the hippocampus of male rats

^○Yusuke MURATA, Masayoshi MORI, Hiroki TERAI, Kenji OHE, Munechika ENJOJI (Department of Pharmacotherapeutics, Faculty of Pharmaceutical Sciences, Fukuoka University, Fukuoka, Japan)

4:48 PM - 4:56 PM

[CNP-P14-2] Post Marketing Survey of Clozapine in treatment-resistant schizophrenia patients in Japan -sub analyses by patients' background factors-

^○Kazuhiro TORIYAMA¹, Tomomi MIKAMI², Yoshihisa SATOU³, Takayoshi SASAJIMA² (1. Medical division, Novartis Pharma K.K., Tokyo Japan, 2. Japan Development, Novartis Pharma K.K., Tokyo Japan, 3. Regulatory Office, Novartis Pharma K.K., Tokyo Japan)

4:56 PM - 5:04 PM

[CNP-P14-3] Reports regarding adverse drug reaction in pharmacovigilance of paliperidone palmitate (Xeplion®)

^○Akihide WAKAMATSU, Takeshi KOYAMA, Hirokazu KAWAMATA, Akiko FUJINO, Rami SUZUKI (Janssen Pharmaceuticals KK)

5:04 PM - 5:12 PM

[CNP-P14-4] The validity and reliability of the Japanese version of Glasgow Antipsychotic Side-effects Scale for Clozapine（GASS-C）

^○Kohei KITAGAWA¹, Ryuhei SO², Nobuyuki NOMURA^{3, 4}, Yuya MIZUNO⁵, Hiroyuki UCHIDA³, Fuminari MISAWA⁴, Masafumi KODAMA^{1, 2}, Hiroyoshi TAKEUCHI³ (1. Department of Clinical Research, Okayama Psychiatric Medical Center, 2. Department of Psychiatry, Okayama Psychiatric Medical Center, 3. Department of Neuropsychiatry, Keio University School of Medicine, 4. Department of Psychiatry, Yamanashi Prefectural Kita Hospital, 5. Institute of Psychiatry, Psychology and Neuroscience, King's College London)